GeNeuro SA (FRA:GEM)

Market Cap	876.05K
Revenue (ttm)	n/a
Net Income (ttm)	-14.76M
Shares Out	n/a
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,389
Open	0.0262
Previous Close	0.0300
Day's Range	0.0262 - 0.0262
52-Week Range	0.0200 - 0.6300
Beta	n/a
RSI	41.38
Earnings Date	Feb 6, 2026

About GeNeuro

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development progra...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 17
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GEM